Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 2/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426408 | 1.00 | S1PR1 (0.52) | S1PR1S1PR3S1PR5CHRNB2CHRNA7 | |
| SCHEMBL3425956 | 1.00 | S1PR1 (0.52) | S1PR1S1PR3S1PR5CHRNB2CHRNA7 | |
| SCHEMBL27685420 | 1.00 | S1PR1 (0.52) | S1PR1S1PR3S1PR5CHRNB2CHRNA7 | |
| SCHEMBL3425965 | 1.00 | S1PR1 (0.52) | S1PR1S1PR3S1PR5CHRNB2CHRNA7 | |
| SCHEMBL2850062 | 0.98 | S1PR1 (0.50) | S1PR1S1PR3S1PR5CHRNB2CHRNA7 | |
| SCHEMBL3425018 | 0.92 | S1PR1 (0.44) | S1PR1S1PR3S1PR5CHRNB2CHRNA7 | |
| SCHEMBL3265494 | 0.92 | S1PR1 (0.49) | S1PR1S1PR3S1PR5CHRNB2CHRNA7 | |
| SCHEMBL27656406 | 0.86 | S1PR1 (0.43) | S1PR1S1PR3S1PR5CHRNB2CHRNA7 | |
| SCHEMBL28761544 | 0.86 | CYP1A2 (0.42) | S1PR1S1PR3S1PR5CHRNB2CHRNA7 | |
| SCHEMBL9818802 | 0.79 | S1PR1 (0.61) | S1PR1S1PR3S1PR5CHRNB2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682504-B1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20100189708-A1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-7741340-B2 | Hydroxy piperidine derivatives to treat gaucher disease | AMICUS THERAPEUTICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1682504-A4 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS INC (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1682504-A2 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | Amicus Therapeutics Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050130972-A1 | Hydroxy piperidine derivatives to treat gaucher disease | AMICUS THERAPEUTICS, INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005046612-A2 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | AMICUS THERAPEUTICS INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100189708-A1 | HYDROXY PIPERIDINE DERIVATIVES TO TREAT GAUCHER DISEASE | GBA1, GAA, GBA2 | S1PR1 905/4885S1PR3 947/4885S1PR5 1591/4885 |
| US-20050130972-A1 | Hydroxy piperidine derivatives to treat gaucher disease | GBA1, GAA, GBA2 | S1PR1 905/4885S1PR3 947/4885S1PR5 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.